Skip to content

OCT in Diagnosis of Irregular Corneas

Optical Coherence Tomography-Aided Differential Diagnosis and Treatment of Irregular Corneas

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03504800
Enrollment
445
Registered
2018-04-20
Start date
2018-05-01
Completion date
2031-02-28
Last updated
2025-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Corneal Dystrophy, Corneal Opacity, Keratoconus

Keywords

OCT, Keratoconus

Brief summary

This main goal of this study is to improve the detection, classification, monitoring, and treatment of irregular corneas due to keratoconus, warpage, dry eye, scar, stromal dystrophies, and other corneal conditions. The primary goal will be achieved by using optical coherence tomography (OCT) to: 1. Develop an OCT-based system to classify and evaluate corneal-shape irregularities. 2. Develop OCT metrics for more sensitive detection of keratoconus progression. 3. Develop OCT-and-topography guided phototherapeutic keratectomy (PTK) for irregular corneas.

Interventions

DEVICEOptical Coherence Tomography

This device will be used to tightly classify corneal irregularities and determine eligibility of candidates from Group A into Groups B & C.

Sponsors

Oregon Health and Science University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
14 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

GROUP A: * Keratoconus: 1. CDVA ≥ 20/25 in the better eye; and both of the following in the worse eye 2. Topography characteristic of keratoconus or pellucid marginal degeneration * Contact lens-related corneal warpage: 1. Contact lens use; and 2. Topography irregularities * Dry eye: 1. Symptoms of dry eye documented by Ocular Surface Disease Index (OSDI) questionnaire score ≥ 30; and 2. Topography irregularities 3. Presence of punctate epithelial erosion on exam with surface staining 4. Aqueous deficiency or evaporative dry eye * Epithelial basement membrane dystrophy (EBMD): 1. Negative corneal fluorescein staining; and 2. Corneal opacities; and 3. Topography irregularities * Stromal addition or subtraction: 1. Scars; or 2. Salzmann's degeneration; or 3. Stromal dystrophies; or 4. Complication (visual complaints) after LASIK or photorefractive keratectomy (PRK) * Stromal distortion: 1. Radial keratectomy (RK); or 2. Corneal transplants. * Normal controls: 1. Healthy eyes with no previous eye procedures/surgeries. GROUP B: Participants will be selected from the keratoconus population in Group A based on topography findings. GROUP C: Participants will be selected from the stromal addition/subtraction and stromal distortion populations of Group A if they have vision primarily limited by scars, dystrophy, or high astigmatism that could benefit from PTK.

Exclusion criteria

(all groups): * Inability to give informed consent. * Inability to maintain fixation for OCT imaging. * Inability to commit to required study visits. * Eyes with concurrent cataract, retinal disease, glaucoma, or other eye conditions that may limit the visual outcome after surgery. * Previous corneal surgeries if considered as a keratoconus participant. * Pregnancy or breastfeeding.

Design outcomes

Primary

MeasureTime frameDescription
Develop OCT-based system to classify and evaluate corneal-shape irregularities1 dayClinical classification of keratoconus, epithelial deformation, stromal addition/subtraction, stromal distortion, and healthy controls by OCT. Primary measurements will be corneal and epithelial thicknesses assessed in micron units.
Develop OCT metrics for more sensitive detection of keratoconus progression4 yearPrimary measurements will be OCT corneal and epithelial thicknesses assessed in micron units.
Develop OCT- and topography-guided phototherapeutic keratectomy (PTK) for irregular corneas1 yearThe primary goal is to improve the post-procedural outcome of uncorrected and best corrected visual acuity. This will be measured in feet by conventional Snellen fraction of 20/xx.

Countries

United States

Contacts

Primary ContactHumberto Martinez, COT
martinhu@ohsu.edu503-494-7712
Backup ContactDenny Romfh, OD
romfhd@ohsu.edu503-494-4351

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026